Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sham Mailankody

Showing results (131-140 of 174) with videos related to

Pageof 18
Sort By:
Blood Cancer Journal|April 21, 2022
Nutrition perceptions, needs and practices among patients with plasma cell disordersMaria A Malik, Nathan W Sweeney, Mohammad Jafri, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific AntibodiesIssam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
Medrxiv : the Preprint Server for Health Sciences|June 25, 2020
COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centersMalin Hultcrantz, Joshua Richter, Cara Rosenbaum, et al.
American Journal of Hematology|January 2, 2023
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approachMatthew J Pianko, Timothy Tiutan, Andriy Derkach, et al.
Blood Advances|August 12, 2020
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignanciesTania Jain, Andrea Knezevic, Martina Pennisi, et al.
JCO Oncology Practice|September 16, 2025
Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up DosesIssam S Hamadeh, Lisa Modelevsky, Amelia Chan, et al.
Blood Advances|April 10, 2024
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapyIssam S Hamadeh, Tala Shekarkhand, Colin Rueda, et al.
Blood Advances|March 6, 2025
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up DosingCarlyn R Tan, Alice X Wang, David Nemirovsky, et al.
Blood Cancer Journal|July 2, 2025
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignanciesSigrun Einarsdottir, Stephanie Lobaugh, Danny Luan, et al.
Blood Advances|May 2, 2025
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple MyelomaBenjamin O Adegbite, Carlyn Rose Tan, Tala Shekarkhand, et al.
Pageof 18

Showing results (131-140 of 174) with videos related to

Sort By:
Pageof 18
Blood Cancer Journal|April 21, 2022
Nutrition perceptions, needs and practices among patients with plasma cell disordersMaria A Malik, Nathan W Sweeney, Mohammad Jafri, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific AntibodiesIssam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
Medrxiv : the Preprint Server for Health Sciences|June 25, 2020
COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centersMalin Hultcrantz, Joshua Richter, Cara Rosenbaum, et al.
American Journal of Hematology|January 2, 2023
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approachMatthew J Pianko, Timothy Tiutan, Andriy Derkach, et al.
Blood Advances|August 12, 2020
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignanciesTania Jain, Andrea Knezevic, Martina Pennisi, et al.
JCO Oncology Practice|September 16, 2025
Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up DosesIssam S Hamadeh, Lisa Modelevsky, Amelia Chan, et al.
Blood Advances|April 10, 2024
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapyIssam S Hamadeh, Tala Shekarkhand, Colin Rueda, et al.
Blood Advances|March 6, 2025
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up DosingCarlyn R Tan, Alice X Wang, David Nemirovsky, et al.
Blood Cancer Journal|July 2, 2025
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignanciesSigrun Einarsdottir, Stephanie Lobaugh, Danny Luan, et al.
Blood Advances|May 2, 2025
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple MyelomaBenjamin O Adegbite, Carlyn Rose Tan, Tala Shekarkhand, et al.
Pageof 18